Loading...
XNASVANI
Market cap72mUSD
Jan 08, Last price  
1.22USD
1D
-3.17%
1Q
9.91%
IPO
-70.53%
Name

Vivani Medical Inc

Chart & Performance

D1W1MN
XNAS:VANI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
79.02%
Rev. gr., 5y
-14.98%
Revenues
0k
1,367,2241,564,9333,397,8528,950,0003,985,0007,964,0006,896,0003,379,0000000
Net income
-26m
L+292.41%
-16,279,127-22,968,925-35,201,247-20,018,000-33,179,000-28,516,000-35,094,000-33,592,000-9,279,000-12,132,000-6,537,000-25,652,000
CFO
-24m
L+26.15%
-15,321,214-17,426,862-17,092,342-20,549,000-25,070,000-23,947,000-29,810,000-27,629,000-7,619,000-10,950,000-18,787,000-23,699,000
Earnings
Mar 24, 2025

Profile

As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.
URL
http://www.secondsight.com/
IPO date
Nov 19, 2014
Employees
50
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
27,322
21,622
Unusual Expense (Income)
NOPBT
(27,322)
(21,622)
NOPBT Margin
Operating Taxes
(7,352)
Tax Rate
NOPAT
(27,322)
(14,270)
Net income
(25,652)
292.41%
(6,537)
-46.12%
Dividends
Dividend yield
Proceeds from repurchase of equity
133
16
BB yield
-0.26%
-0.05%
Debt
Debt current
2,766
955
Long-term debt
40,009
1,910
Deferred revenue
Other long-term liabilities
1,177
Net debt
22,121
(43,577)
Cash flow
Cash from operating activities
(23,699)
(18,787)
CAPEX
(887)
(338)
Cash from investing activities
(887)
(338)
Cash from financing activities
133
63,390
FCF
(46,706)
(13,447)
Balance
Cash
20,654
45,076
Long term investments
1,366
Excess cash
20,654
46,442
Stockholders' equity
(98,293)
36,299
Invested Capital
141,133
8,964
ROIC
ROCE
EV
Common stock shares outstanding
50,853
38,241
Price
1.02
20.04%
0.85
 
Market cap
51,870
59.63%
32,493
 
EV
73,991
(11,084)
EBITDA
(26,965)
(21,241)
EV/EBITDA
0.52
Interest
7,352
Interest/NOPBT